Pioneering solutions, saving lives
Research is critical to combatting brain disease and improving the lives of those impacted, today and in the future.
Conducted by The Royal Melbourne Hospital’s Departments of Neurology and Neurosurgery, the active research programs and clinical trials supported by the Foundation cover an extensive breadth of neurological conditions.
Patients wishing to participate are encouraged to view the relevant trial and contact the trial co-ordinator for more information.
| Brain Tumour / Neurosurgery: | NsurgClerk@mh.org.au |
| Dementia: | DementiaTrials@mh.org.au |
| Epilepsy: | EpilepsyCoordinator@mh.org.au |
| Huntington’s Disease: | RMHHuntingtonDiseaseStudies@mh.org.au |
| Movement Disorders: | PDNurse@mh.org.au |
| Multiple Sclerosis: | MSClinic@mh.org.au |
| Neurophysiology: | RMH-ClinicalNeurophysiology@mh.org.au |
| Stroke: | RMH-StrokeResearchTeam@mh.org.au |
| General: | Neuro.Foundation@mh.org.au |
Master Screening Study to Determine Individuals with Potential Trial Eligibility for Alzheimer’s Disease Studies as Assessed by Biomarker Status and Cognition
A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults with Refractory Relapsing or Progressing Multiple Sclerosis
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Intravenous Prasinezumab In Participants With Early-Stage Parkinson’s Disease
Evaluation of patients admitted to ICU following endovascular thrombectomy for acute ischaemic stroke
A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chronic migraine in adults